Product information and disease descriptionPlace of product in therapyDisease description
Long-term morbidity
7 evidence topics · 6 sources
Myasthenic crisis: frequency, triggers, and outcomes
“Myasthenic crisis (MC) is a life-threatening manifestation of myasthenia gravis (MG) defined by respiratory insufficiency that requires the use of invasive or non-invasive ventilation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MC occurs in approximately 15%-20% of patients with MG usually within the first 2 to 3 y of the disease course.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Many crises have a specific trigger with respiratory infections being most common; however, no specific trigger is found in 30%-40% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MG patients with a history of MC, severe disease, oropharyngeal weakness, muscle-specific kinase (MuSK) antibodies and thymoma appear to be at higher risk.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mortality rate in United States cohorts is less than 5% and mortality in MC seems to be driven by age and other medical co-morbidities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A myasthenic crisis (MC) is a more severe, life-threatening escalation of muscle weakness that leads to respiratory failure, necessitating intensive care unit admission with assisted ventilation, usually requiring an inpatient stay period of several weeks, often in the range of 2–4 weeks” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 20% of patients with gMG are estimated to experience MC during a period of 3 years or longer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Myasthenic crisis: Ontario, Canada, population-based incidence
Exacerbations and crises: predictors and inpatient use, United States generalized myasthenia gravis
“Among 6,195 patients with gMG (mean age: 61.1 years; female: 49.1%), higher event risk was associated with use of immunoglobulin [hazard ratio (HR) = 1.54], baseline dysarthria (HR = 1.45), general and other muscle-specific weaknesses (HR = 1.38), use of non-steroidal immunosuppressants (HR = 1.37), dysphagia (HR = 1.28), weight loss (HR=1.27), dyspnea (HR = 1.23), ptosis (HR = 1.20), absence of other autoimmune disorders (HR=1.18), and male sex (HR = 1.15; all p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After re-weighting, patients with a clinical event had higher number of inpatient admissions [rate ratio (RR) = 6.02], emergency visits (RR = 1.91), and outpatient visits (RR = 1.58; all p < 0.05) in the 12 months post-index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization trends: United States, 2010 to 2019
“Hospitalization rates for 19,715 unique adult patients and 56,822 admissions increased from 2010 to 2019 at an average annualized rate of 4.9% (MG noncrisis: 4.4%; MG crisis: 6.8%; all p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average LOS was stable over the study period, ranging from 11.3 to 13.1 days, but was consistently longer for MG crisis admissions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Refractory disease: persistent moderate or severe weakness
Glucocorticoid toxicity: United States commercially insured adults with generalized myasthenia gravis
“Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the study period, incident GC toxicities were more common among patients in the any GC use cohort than the no GC use cohort (61.9% vs 52.3% with ≥1 toxicity), with a trend of increasing incidence with increasing GC use (≥5 mg/d: 62.9%; ≥10 mg/d: 67.3%; all P < .001” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, a greater proportion of patients with any GC use than no GC use had ≥3 incident GC toxicities (16.5% vs 9.5%), with this proportion rising with mean PEDD ≥5 mg (18.9%) and mean PEDD ≥10 mg (22.8%; all P <.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both acute and chronic incident GC toxicities were more common in the any GC use cohort than the no GC use cohort (acute: 28.5% vs 19.1%; chronic: 51.9% vs 43.8%; both P <.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection; chronic toxicities were dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since claims data do not contain reasons for diagnoses, toxicities could not be confirmed to be related to GC use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote